Jim Cramer Says Moderna, Inc. (MRNA) Has Been ‘One Of The Biggest Disappointments Of The Year’; Is Moderna a Bad-News Buy for 2025? and other C-Virus related stories

Jim Cramer Says Moderna, Inc. (MRNA) Has Been ‘One Of The Biggest Disappointments Of The Year’:

We recently compiled a list of the Jim Cramer Recently Discussed These 17 Stocks And Chinese Hackers. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other stocks Jim Cramer recently discussed.

Jim Cramer’s appearance on Squawk on the Street aired on January 17th covered a wide variety of topics. As the day was in the final few days of the outgoing Biden administration, Cramer shared his thoughts about the policies of the outgoing and incoming governments. Commenting on President-elect Trump’s nominee for Treasury Secretary, Scott Bessent’s confirmation hearing Cramer shared that he “liked it.” He shared the reasons behind his approval.

“Well, I think that, in the end, he respects the process. I think a lot of the, I think there’s the process respecters and the process undoers,” Cramer thinks. He “felt that Secretary Bessent, soon to be, I gotta be careful, who knows, he’s talking about, there was a give and take. There was a moment when he was give and take with Senator Sanders.” While during their exchange, Cramer thought “Sanders thought that he was gonna, tee off on Sanders.” However, Bessent and Sanders actually “had common ground, and there was a lot of respect. And then I think Sanders had nothing to say, it was kind of like, okay,” according to the CNBC host.

Another hot topic in the markets is the President-elect’s potential policies on cryptocurrency. When asked by co-host Sara Eisen about his thoughts on Trump passing an executive order for crypto, Cramer stated “I agree and I think, well look the President-elect has made it no secret that he wants a strategic crypto reserve. So I’m not quite sure where that would be. Not in Fort Knox, it’s kind of, anywhere, right. I would like to make sure the blockchain is severe. I’m trying really hard to get a grip on that reserve because it doesn’t jump out at me.”

One country that Cramer regularly targets in his morning thoughts is China. This time around, he likened China to East Germany. ” We thought East Germany was incredibly powerful. They would go to the Olympics, and we’d say they’re amazing. We thought their schools were really great. And it turned out to be an empty suit,” believes Cramer. China needs “exports, they need everybody, they need help from everyone and they don’t wanna help anyone,” according to him.

In fact, China might be one of the reasons “President-elect Trump was elected,” he shared. Cramer shared that this is “because the Chinese dumped everything in every, of what we used to make. I mean my father sold gift wrap. They wiped out the gift wrap companies. So my father ended up working for the Chinese. They were nice to him.” China’s hostility leads Cramer to “think that we all should be cognizant that the Chinese are not our friends. But they are trying. I think that’s smart to try.” —>READ MORE HERE

Is Moderna a Bad-News Buy for 2025?

Moderna (MRNA 0.89%) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it. This helped the stock to skyrocket, reaching a high of more than $480 at its peak in 2021.

Since then, though, Moderna has traveled along a rough path. Demand for the coronavirus vaccine has dropped significantly, and even the company’s second approved product — respiratory syncytial virus (RSV) vaccine mRESVIA — hasn’t delivered as much revenue as expected. All this has weighed on the stock, which has lost more than 90% since its peak.

On top of this, at the JPMorgan Healthcare conference this week, Moderna lowered its 2025 revenue guidance, and announced more than $1 billion in cost cuts for this year and next. This follows initial spending reductions launched in 2023 to scale back the company’s manufacturing infrastructure.

So, right now, after the stock fell 16% in one trading session on the news, is Moderna a bad-news buy for 2025? Let’s find out.

A disappointing vaccination season

So, let’s consider the bad news first. Moderna has delivered lower levels of revenue than expected in recent times as demand for vaccination fell short of initial expectations. It also lost market share in COVID vaccination during the recent season as competition increased.

This problem may remain as other competitors enter the market or gain in strength — for example, as of this year, vaccine giant Sanofi will co-commercialize Novavax’s coronavirus vaccine, and its experience and infrastructure may help it take market share. —>READ MORE HERE

Follow links below to relevant/related stories and resources:

Many Schools Used COVID Aid on Curriculum and Buildings, Feds Say



These COVID Symptoms Are Red Flags That You Need Medical Attention



USA TODAY: Coronavirus Updates

WSJ: Coronavirus Live Updates

YAHOO NEWS: Coronavirus Live Updates

NEW YORK POST: Coronavirus The Latest

Source

Jesus Christ is King